Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
76 of 180 long COVID-associated genes also linked to ME
It's an acquisition that aims at forming one of the US's largest oncology trial networks
This campaign is to raise awareness about the crucial role helmet usage plays in saving lives
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Angelini Ventures has already invested €125 million in 22 startups
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Subscribe To Our Newsletter & Stay Updated